A new oral drug that can treat anemia, one of the complications of patients with chronic kidney disease, has been approved in Korea. Until now, the standard therapy for treating the disease has been administered with a red blood cell production stimulating injection called EPO (Erythropoietin) or ESA (Erythropoiesis stimulating agent), and attention is being paid to whether a new oral drug with high convenience will replace ESA.

The MFDS approved AstraZeneca Korea's (Roxadustat) 5 items on the 9th.

This drug is used to treat syndrome anemia in patients with chronic nephropathy. In particular, patients who are or are not on dialysis can also be used. It can also replace the ESA injections